Nanoparticle-mediated delivery of IL-2 to T follicular helper cells protects BDF1 mice from lupus-like disease-Reference-Cited by-同舟云学术

Nanoparticle-mediated delivery of IL-2 to T follicular helper cells protects BDF1 mice from lupus-like disease

Published:2021-09-01 Issue:3 Volume:2 Page:185-193
ISSN:2719-4523
Container-title:Rheumatology and Immunology Research
language:en
Short-container-title:

Author:

Ferretti Concetta¹,Horwitz David A.²³,Bickerton Sean⁴,La Cava Antonio¹⁵

Affiliation:

1. Department of Medicine , University of California Los Angeles , Los Angeles , CA , USA

2. Keck School of Medicine , University of Southern California , Los Angeles , CA , USA

3. General Nanotherapeutics , Santa Monica , CA , USA

4. Department of Biomedical Engineering , Yale University , New Haven , CT , USA

5. Dipartimento di Biochimica e. Biotecnologie Mediche , University of Naples Federico II , Naples , Italy

Abstract

Abstract We recently reported that poly lactic-co-glycolic acid (PLGA) nanoparticles (NPs) loaded with interleukin (IL)-2 and targeted to T cells inhibited the development of lupus-like disease in BDF1 mice by inducing functional T regulatory cells (Tregs). Here we show that the protection from disease and the extended survival of BDF1 mice provided by IL-2-loaded NPs targeted to T cells is not only due to an induction of Tregs but also contributed by an inhibition of T follicular helper (TFH) cells. These results identify a dual protective activity of IL-2 in the control of lupus autoimmunity, namely the inhibition of effector TFH cells, in addition to the previously known induction of Tregs. This newly recognized activity of IL-2 delivered by NPs can help better explain the beneficial effects of low-dose IL-2 immunotherapy in systemic lupus erythematosus (SLE), and might be considered as a new strategy to slow disease progression and improve outcomes in lupus patients.

Publisher

Walter de Gruyter GmbH

Link

https://www.degruyter.com/document/doi/10.2478/rir-2021-0024/pdf

Reference40 articles.

1. Mannoor K, Xu Y, Chen C. Natural Autoantibodies and Associated B Cells in Immunity and Autoimmunity. Autoimmunity. 2013;46: 138–147.

2. La Cava A. Antibodies to DNA in Systemic Lupus Erythematosus: A Review and Update. In: Petrelli CT, ed. New Research on Autoantibodies. New York: Nova Science Publishers, 2008:61–86.

3. La Cava A. Overview of the Pathogenesis of Systemic Lupus Erythematosus. In: Tsokos GC, ed. Systemic Lupus Erythematosus. Basic, Applied and Clinical Aspects, 2nd Edn. Waltham: Academic Press, 2020:69–75.

4. He M, Cheng KF, VanPatten S, et al. A Structural Investigation of FISLE-412, A Peptidomimetic Compound Derived from Saquinavir That Targets Lupus Autoantibodies. Bioorg Med Chem Lett. 2017;27:4725–4729.

5. Wallace DJ. Clinical and Pharmacological Experience with LJP-394. Exp Opin Invest Drugs 2001;10:111–117.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nanoparticles loaded with IL-2 and TGF-β promote transplantation tolerance to alloantigen;Frontiers in Immunology;2024-07-26

2. Th1-related transcription factors and cytokines in systemic lupus erythematosus;Frontiers in Immunology;2023-12-18

3. Low-dose interleukin-2 therapy in systemic lupus erythematosus;Rheumatology and Immunology Research;2023-09-01

4. Peptide-based immunotherapy in lupus: Where are we now?;Rheumatology and Immunology Research;2023-09-01

5. Delivery of AntagomiR-7 through polymer nanoparticles for assisting B Cell to alleviate systemic lupus erythematosus;Frontiers in Bioengineering and Biotechnology;2023-04-19